Design and Analysis of Phase I Clinical Trials
From MaRDI portal
Publication:3201544
DOI10.2307/2531693zbMATH Open0715.62241OpenAlexW2054383376WikidataQ44888410 ScholiaQ44888410MaRDI QIDQ3201544FDOQ3201544
Publication date: 1989
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2531693
Recommendations
- The treatment versus experimentation dilemma in dose finding studies
- A new look at evaluating MTD designs in cancer research
- Bayesian optimal designs for phase I clinical trials
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design
- An assessment of up- and down designs and associated estimators in phase I trials
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)
Cited In (77)
- Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials
- A conversation with Nancy Flournoy
- A new look at evaluating MTD designs in cancer research
- Design and Analysis of Clinical Trials
- Approximate dynamic programming and its applications to the design of Phase I cancer trials
- A new design of the continual reassessment method
- A note on continual reassessment method
- An assessment of up- and down designs and associated estimators in phase I trials
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
- Designs foe phase i cancer clinical trials with differentiation of graded toxicity
- Operating characteristics of the standard phase I clinical trial design.
- Optimal designs for dose-escalation trials and individual allocations in cohorts
- A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents
- Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- A class of designs for Phase I cancer clinical trials combining Bayesian and likelihood approaches
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
- Optimal Bayesian-feasible dose escalation for cancer phase I trials
- A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method
- Testing simultaneous hypotheses in pharmaceutical trials: a bayesian approach
- Unifying CRM and EWOC designs for phase I cancer clinical trials
- Title not available (Why is that?)
- Continual reassessment method for partial ordering
- Sequential method of estimating the LD50 using a modified up-and-down rule
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- Likelihood‐Based Experimental Design for Estimation of Ed 50
- Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
- A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials
- Title not available (Why is that?)
- Methodology and application of adaptive and sequential approaches in contemporary clinical trials
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
- A semi-Markov model for patient progression through clinical trials
- Theoretical study of the continual reassessment method
- Semiparametric Dose Finding Methods for Partially Ordered Drug Combinations
- Analyzing longitudinal count data from adaptive clinical trials: a weighted generalized quasi-likelihood approach
- SEQUENTIAL METHODS IN CLINICAL TRIALS*
- A Parallel Phase I/II Clinical Trial Design for Combination Therapies
- Adaptive clinical trial designs for phase I cancer studies
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- The role of minimal sets in dose finding studies
- A sequential design for maximizing the probability of a favourable response
- Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials
- The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes
- Retrospective Analysis of Sequential Dose‐Finding Designs
- On the consistency of the continual reassessment method with multiple toxicity constraints
- Designs for Single- or Multiple-Agent Phase I Trials
- Performance Measures in Dose‐Finding Experiments
- Design issues for generalized linear models: a review
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- Group up-and-down designs for dose-finding
- Continual reassessment and related dose-finding designs
- Stochastic approximation and modern model-based designs for dose-finding clinical trials
- Design efficiency in dose finding studies
- Title not available (Why is that?)
- Dose-Finding with Two Agents in Phase I Oncology Trials
- Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
- The adaptive accelerated biased coin design for phase I clinical trials
- PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials
- A continual reassessment method without undue risk of toxicity
- A modified Huber loss function for continual reassessment methods in clinical trials
- A simulation-free approach to assessing the performance of the continual reassessment method
- Fractional accumulative calibration-free odds (f-aCFO) design for delayed toxicity in phase I clinical trials
- REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
- A novel approach for propensity score matching and stratification for multiple treatments: application to an electronic health record-derived study
- Comparative review of novel model-assisted designs for phase I/II clinical trials
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials
- A machine learning compatible method for ordinal propensity score stratification and matching
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials
- Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
- Early completion of phase I cancer clinical trials with Bayesian optimal interval design
- Comment on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies
- Dose finding studies for therapies with late-onset toxicities: a comparison study of designs
- Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment
- Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design
- Two-stage phase II trials with early stopping for effectiveness and safety as well as ineffectiveness or harm
This page was built for publication: Design and Analysis of Phase I Clinical Trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3201544)
